1.Comparison of Radiation Therapy and Combined Chemotherapy and Radiation Therapy for Locally Advanced Head and Neck Cancer.
Gyu Taeg LEE ; Jae Ho BYUN ; Kwon HWANGBO ; Ji Oh MOK ; Eun Seuk KIM ; Jong Ho WON ; Seung Ho BAICK ; Doo Ho CHOI ; Dae Sik HONG ; Hee Sook PARK
Journal of the Korean Cancer Association 1997;29(4):616-622
PURPOSE: In locally advanced head and neck cancer, radiation therapy is currently unsatisfactory because the end result is often limited regional disease control and survival. A clinical study was carried out to compare the effectiveness between the radiation therapy and the combined chemotherapy and radiation therapy. MATERIALS AND METHOD: Thirty-six patients with previously untreated, locally advanced squamous cell carcinoma of the head and neck were treated with radiotherapy alone and combined chemo-radiotherapy. Induction chemotherapy was administered 2~3 cycles, consisting of intravenous cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1000 mg/m2/day for 5 days as a continuous infusion) every 4 weeks followed by 7~8 weeks of radiation therapy for a total dose of 60~75 Gy. RESULTS: 1) Among 36 locally advanced head and neck cancer, 17 patients received radiation therapy alone and 19 patients received combined chemo-radiotherapy, respectively. 2) Response rate was 47% (complete response 29%, and partial response 18%) in radiation therapy group and 79% (complete response 37%, and partial response 42%) in combined chemo-radiotherapy group (p<0.05). 3) In median survival, radiation therapy group was 13 months and combined chemo- radiotherapy group was 15 months. Both groups were not significantly different (p>0.05). 4) Treatment related mortality was not noted, but the toxic effects were seen on the half cases of the both groups. Grade II toxicities were similar between the two arms. CONCLUSION: Combined chemotherapy and radiation therapy was more effective in local control but not superior in survival than radiation therapy alone. Continuous evaluation and identification of proper sequence for the therapeutic modality is supposed to prolong the survival of patients.
Arm
;
Carcinoma, Squamous Cell
;
Cisplatin
;
Drug Therapy*
;
Fluorouracil
;
Head and Neck Neoplasms*
;
Head*
;
Humans
;
Induction Chemotherapy
;
Mortality
;
Neck
;
Radiotherapy
2.Surgical Treatment of Stage IIIA Non Small Cell Lung Cancer ( NSCLC ).
Kyung Young CHUNG ; Gi Pyo HONG ; Chang Suh KIM ; Kil Dong KIM ; Joo Hang KIM ; Dong Whan SHIN
The Korean Journal of Thoracic and Cardiovascular Surgery 1999;32(2):144-150
BACKGROUND: Surgery has been considered the most effective and standard treatment modality in non-small cell lung cancer(NSCLC). However in stage IIIA lung cancer, the role of surgery is still controversial. To evaluate the role of surgery for stage IIIA NSCLC, we investigated the survival after surgery and the prognostic factors. MATERIAL AND METHOD: We evaluated 158 consecutive cases of stage IIIA NSCLC patients operated on between 1990 and 1996. There were 130 male patients and 28 female patients, and the mean age was 58.5 years. All patients except one underwent lung resection beyond lobectomy and extended mediastinal dissection. Postoperative adjuvant therapy were undertaken in 145(94.8%) patients. All patients(153) were followed and the mean follow-up period was 21.4months. RESULT: Twenty nine cases of the postoperative complications developed in 25 patients (15.8%). There were 5 operative mortality cases(3.2%) and the main cause of death was acute respiratory distress syndrome (ARDS). Local or distant recurrences developed in 84 patients(54.9%). The 5-year survival of 153 patients was 29.6% and the median survival time was 18.0 months. The 5-year survival of non N2 disease group(36.8%) was better than that of N2 disease group(26.6%)(p=0.35) and the 5-year survival of squamous cell carcinoma (38.1%) was better than that of adenocarcinoma(25.7%)(p=0.39) however there were no significant differences. Regarding the postoperative adjuvant therapy, in combined therapy group(84 patients), radiotherapy group(37 patients) and chemotherapy group(24 patients), the 5-year survival were 31.3%, 32.4%, and 14.6% respectively. There was no difference of survival between radiotherapy and combined therapy group(p=0.31), however the survival of the combined therapy group was better than the chemotherapy group(p=0.005). The survival of the complete resection group(31.9%) was better than the incomplete resection group(16.6%) however there was no significant difference(p=0.19). CONCLUSION: These observations indicate that the good 5-year survival(29.6%) in patients with stage IIIA NSCLC result from the agressive surgical treatment including extensive mediastinal nodes dissection.
Carcinoma, Non-Small-Cell Lung
;
Carcinoma, Squamous Cell
;
Cause of Death
;
Drug Therapy
;
Female
;
Follow-Up Studies
;
Humans
;
Lung
;
Lung Neoplasms
;
Male
;
Mortality
;
Postoperative Complications
;
Radiotherapy
;
Recurrence
;
Respiratory Distress Syndrome, Adult
;
Small Cell Lung Carcinoma*
3.VEGF as a Predictor for Response to Definitive Chemoradiotherapy and COX-2 as a Prognosticator for Survival in Esophageal Squamous Cell Carcinoma.
Mee Sun YOON ; Taek Keun NAM ; Ji Shin LEE ; Sang Hee CHO ; Ju Young SONG ; Sung Ja AHN ; Ik Joo CHUNG ; Jae Uk JEONG ; Woong Ki CHUNG ; Byung Sik NAH
Journal of Korean Medical Science 2011;26(4):513-520
We investigated the patterns of pretreatment expression of the epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and cyclooxygenase-2 (COX-2) by immunohistochemical staining and determined their correlation with treatment response and survival in 44 patients with esophageal squamous cell carcinoma (ESCC) treated with definitive concurrent chemoradiotherapy (CCRT). The definitive CCRT consisted of a median dose of 54 Gy (range: 40.0-68.4 Gy) and two cycles of concurrent administration of mostly 5-fluorouracil + cisplatinum. High expression of EGFR, VEGF, and COX-2 was found in 79.5%, 31.8%, and 38.6%, respectively. The Cox regression analysis for overall survival (OS) showed that both the treatment response and COX-2 expression were significant. The 3-yr OS rates of patients that achieved a complete response and those that did not were 46.7% and 5.3%, respectively (P = 0.006). The logistic regression analysis for treatment response with various parameters showed that only a high expression of VEGF was significantly associated with a complete response. Unlike other well-known studies, higher expression of VEGF was significantly correlated with a complete response to CCRT in this study. However, higher expression of COX-2 was significantly associated with shorter survival. These results suggest that VEGF might be a predictive factor for treatment response and COX-2 a prognostic factor for OS in patients with ESCC after definitive CCRT.
Aged
;
Antineoplastic Agents/therapeutic use
;
Carcinoma, Squamous Cell/drug therapy/*mortality/radiotherapy/*therapy
;
Cisplatin/therapeutic use
;
Combined Modality Therapy
;
Cyclooxygenase 2/*metabolism
;
Drug Therapy, Combination
;
Esophageal Neoplasms/drug therapy/*mortality/radiotherapy/*therapy
;
Female
;
Fluorouracil/therapeutic use
;
Humans
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Predictive Value of Tests
;
Radiation Dosage
;
Receptor, Epidermal Growth Factor/metabolism
;
Regression Analysis
;
Survival Rate
;
Vascular Endothelial Growth Factor A/*metabolism
4.Significance of p53 as a Prognostic Factor in Non-Small Cell Lung Carcinoma.
In Seok JANG ; Sangho RHIE ; Jung Ho HAN ; Kwhanmien KIM ; Jhingook KIM ; Young Mog SHIM
The Korean Journal of Thoracic and Cardiovascular Surgery 2004;37(8):672-685
BACKGROUND: The treatment results of the advanced lung carcinoma is not satisfactory with the present therapeutic modalities: surgical resection, anti-cancer chemotherapy, and radiotherapy or combination therapy. To predict the prognosis of the non-small-cell lung carcinoma, TNM classification has been was as the basic categorization; however, it has been not satisfactory. It is necessary to consider the causes and the prognosis of the lung carcinoma from another points of view rather the conventional methods. We intended to find out the relationship between the major apoptotic factor, p53 gene and the prognosis of the patient with lung carcinoma. MATERIAL AND METHOD: Three hundreds and fifty-nine patients with lung carcinoma who underwent surgery were analysed. We observed p53 protein accumulated in the cellular nuclei. The p53 protein was detected by immuno-histo-chemical method. We collected information of the patient retrospectively. RESULT: p53 protein densities were observed in 40% in average as a whole. The protein density was 44 percent in man, 25 percent in woman, 49 percent in the squamous cell carcinoma, and 38 percent in the adenocarcinoma. There were significant correlations between the p53 protein density and the mortality in the squamous cell carcinoma (p=0.025), follow-up duration in TNM stage I group (p=0.010), and follow-up duration in the lobectomy patient group (p=0.043), and tumor cell differentiation (p=0.009). p53 protein densities were significantly different between the lobectomy and the pneumonectomy group (p=0.044). CONCLUSION: The authors found that p53 protein had some correlations with the prognosis of the lung cancer partially in some factors. We suggest the p53 protein density could be used as a marker of prognosis in the non-small-cell lung carcinoma.
Adenocarcinoma
;
Apoptosis
;
Carcinoma, Non-Small-Cell Lung
;
Carcinoma, Squamous Cell
;
Cell Differentiation
;
Classification
;
Drug Therapy
;
Female
;
Follow-Up Studies
;
Genes, p53
;
Humans
;
Lung Neoplasms
;
Lung*
;
Mortality
;
Pneumonectomy
;
Prognosis
;
Radiotherapy
;
Retrospective Studies
5.Prognostic factors in nasopharyngeal carcinoma in childhood and adolescence.
Ka-jia CAO ; Yin LI ; Guo-feng XIE ; Ming-huang HONG
Chinese Journal of Oncology 2006;28(2):134-137
OBJECTIVETo analyze the prognostic factors affecting long-term result in pediatric or adolescent nasopharyngeal carcinoma.
METHODSFrom January 1984 to December 1998, 117 cases of pediatric and adolescent nasopharyngeal carcinoma proven by pathology were treated by radiotherapy and/or chemotherapy. Their data were retrospectively analyzed. Of the 117 patients, 35 received chemotherapy before radiotherapy, 36 were treated with continuous radiotherapy and the other 81 with split-course radiotherapy. A dose of 56 - 80 Gy/6 - 13 weeks (66.32 +/- 4.72 Gy) was given in the nasopharynx and 47 - 73 Gy/5 - 13 weeks (57.90 +/- 5.80 Gy) in the neck. The survival rates were assessed by Kaplan-Meier analysis and the survival curves compared by Log-rank test. The multivariate analysis was conducted by Cox model.
RESULTSThe 1-, 3- and 5-year overall survival rate was 86.3%, 66.6% and 56.4%, respectively; and disease-free survival rate at 1, 3 and 5 years was 71.8%, 53.9% and 50.4%, respectively. A monovariate analysis showed that the age (P = 0.0015), mode of biopsy (P = 0.0234), N stage (P = 0.0001), mode of irradiation (P = 0.0027), chemotherapy (P = 0.0056) and short-term result (P = 0.0000) were the significant prognostic factors. The multivariate analysis demonstrated that the age (P = 0.027), N stage (P = 0.048), mode of irradiation (P = 0.009) and short-term result (P = 0.000) were the factors influencing prognosis of nasopharyngeal carcinoma in childhood and adolescence. Radiation-induced brain injuries were observed in 17 patients including brain stem injury in 1 (0.9%), temporal brain lobes in 3 (2.6%) and cranial nerves in 13 (11.1%).
CONCLUSIONThe mode of irradiation, N stage and short-term result are the significantly influencing factors of prognosis in pediatric and adolescent nasopharyngeal carcinoma. Radiation-induced brain injuries during radiotherapy should not be overlooked.
Adolescent ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Carcinoma, Squamous Cell ; drug therapy ; mortality ; pathology ; radiotherapy ; Child ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Male ; Nasopharyngeal Neoplasms ; drug therapy ; mortality ; pathology ; radiotherapy ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Prognosis ; Radiation Injuries ; etiology ; Radiotherapy, High-Energy ; adverse effects ; Retrospective Studies ; Survival Rate
6.Surgical Resection of Small Cell Lung Cancer ( SCLC ).
Kyung Young CHUNG ; Gi Pyo HONG ; Kil Dong KIM ; Dae Jun KIM ; Joo Hang KIM
The Korean Journal of Thoracic and Cardiovascular Surgery 1998;31(12):1195-1199
Bafckground: Thr role and indication of surgery in the treatment of small cell lung cancer (SCLC) is currently limited and unsettled. MATERIAL AND METHOD: We analyzed the surgical results of 9 patients with SCLC at Yosei Medical Center from January 1990 to December 1996. There were 8 males and 1 female, and their mean age was 57.2 years (range; 35-76). Preoperatively SCLC was confirmed in 5, but the other 4 cases were diagnosed as undifferentiated squamous cell carcinoma. All patients underwent pulmoinary resection (lobectomy;5, lobectomy, segmentectomy and en-bloc resection of rib;1, bilobectomy; 2, pneumonectomy;1) and mediastinal lymph node dissection. RESULTS: There were no operative mortality with two complications (postoperative bleeding;1, arrhythmia;1). All cases were diagnosed as SCLC histologically and their TNM staging were confirmed as follows: T1N0M0;1, T2N0M0;4, T3N0M0;1, T3N1M0;1, T2N2M0; 1, T4N0M0;1. All patients had received postoperative chemotherapy, and radiotherapy was combined in 4 patients. During follow up period (range 1-63 months; mean 33.0months), there was only one metastasis to pelvic bone among 8 patients without lymph node metastasis, and all patients were alive. On the other hand, among 3 patients who had regional and/or mediastinal lymph node metastasis or T4 lesion, all patients had recurrences (local;2, brain;1), and 2 patients died. CONCLUSION: We suggest that the use of TNM staging is beneficial, and surgical resection should be recommended in the patients with early staged SCLC as an important treatment modality.
Carcinoma, Squamous Cell
;
Drug Therapy
;
Female
;
Follow-Up Studies
;
Hand
;
Humans
;
Lymph Node Excision
;
Lymph Nodes
;
Male
;
Mastectomy, Segmental
;
Mortality
;
Neoplasm Metastasis
;
Neoplasm Staging
;
Pelvic Bones
;
Radiotherapy
;
Recurrence
;
Small Cell Lung Carcinoma*
7.Primary Invasive Vulvar Cancer, Retrospective Study of 23 cases.
Shin Wha LEE ; Min Hyung JUNG ; Kue Rye KIM ; Hang Jo YOO ; Dae Yeon KIM ; Jong Hyeok KIM ; Yong Man KIM ; Young Tak KIM ; Joo Hyun NAM ; Jung Eun MOK
Korean Journal of Obstetrics and Gynecology 2005;48(3):589-596
OBJECTIVE: The vulvar cancer is an uncommon disease among female population. Because of its rare incidence, sufficient clinical studies have not been accomplished. However, the prevelance of vulvar cancer will continue to increase because of rapid growth of senile population. The goal of this study is to review the clinical outcome and prognosis of patients with vulvar cancer through the analysis of their clinical data. METHODS: We have performed a retrospective clinical study on 23 patients diagnosed with primary invasive vulvar cancer at Asan medical center from May, 1989 to December, 2003. We reviewed demographic data, pathologic findings, treatments, stages, complications, prognosis and survival time. RESULTS: The mean age was 58.9 years. The most common symptoms were palpable mass (69.5%) and itching sense (21.7%). Among the 23 patients, 21 patients have underwent operation, and two patients who refused to receive operation underwent radiotherapy only. 3 of 21 patients who were surgically treated underwent neoadjuvant chemotherapy, and 5 patients, adjuvant radiotherapy. Histopathologically, squamous cell carcinoma (69.5%) was dominant, and 15 patients turned out to have stage II disease or greater (60.8%). Among the 21 patients who have underwent operation, postoperative complications occurred in 8 patients (38.0%) and 4 of them had underwent radical vulvectomy and bilateral groin lymph node dissection. The most common postoperative complication was wound breakdown (23.8%). CONCLUSION: Although surgery is the principal treatment in vulvar cancer, radical vulvectomy and bilateral groin lymph node dissection more often result in complications than other operations such as wide local excision and hemivulvectomy. Considering the mortality and morbidity, the prognosis of vulvar cancer is poor, but early diagnosis and adequate treatment according to each individual will improve the outcome and prognosis of vulvar cancer.
Carcinoma, Squamous Cell
;
Chungcheongnam-do
;
Drug Therapy
;
Early Diagnosis
;
Female
;
Groin
;
Humans
;
Incidence
;
Lymph Node Excision
;
Mortality
;
Postoperative Complications
;
Prognosis
;
Pruritus
;
Radiotherapy
;
Radiotherapy, Adjuvant
;
Retrospective Studies*
;
Vulva
;
Vulvar Neoplasms*
;
Wounds and Injuries
8.Nasopharyngeal Carcinoma in Children and Adolescents: Single Institution Study
Jung Yoon CHOI ; Hyoung Jin KANG ; Hee Young JU ; Che Ry HONG ; Il Han KIM ; Sung Hye PARK ; In One KIM ; Kyung Duk PARK ; Hee Young SHIN
Clinical Pediatric Hematology-Oncology 2014;21(2):114-120
BACKGROUND: Nasopharyngeal carcinoma (NPC) is very rare in children and adolescents. The aim of this study was to evaluate clinical characteristics and treatment outcomes of pediatric NPC.METHODS: Medical records of 9 patients treated for NPC at the Seoul National University Children's Hospital between 1988 and 2012 were analyzed retrospectively.RESULTS: The median age at diagnosis was 11 years (range, 9-13 years). One patient had stage II disease, 3 had stage III disease, and 5 had stage IV disease. The histologic subtypes were undifferentiated carcinoma and squamous cell carcinoma in 7 and 2 patients, respectively. All patients were initially treated with cisplatin (100 mg/m2 intravenous [IV] every 4 weeks for 4-6 months), bleomycin (15 unit/m2 IV every 1 weekx7), and fluorouracil (1,000 mg/m2 IV every 4 weeks for 1 year). Eight patients received radiotherapy with doses of 45-59.4 Gy at the primary site and neck nodes. Seven patients (77.8%) achieved complete remission, 1 (11.1%) achieved partial remission, and 1 (11.1%) showed disease progression. Six patients developed fluorouracil-related neurotoxicity; the regimen was changed to cisplatin, epirubicin, and bleomycin in five of the 6 patients. One patient died of progressive disease without responding to treatment. Treatment-related mortality occurred in 1 patient owing to septic shock. Secondary osteosarcoma developed in 1 patient 6 years after treatment. The overall survival was 77.8%, with a median follow-up of 40.8 months (range, 4.5-287.6 months).CONCLUSION: Children and adolescents with advanced NPC treated with combined chemotherapy and radiotherapy have a good survival rate.
Adolescent
;
Bleomycin
;
Carcinoma
;
Carcinoma, Squamous Cell
;
Chemoradiotherapy
;
Child
;
Cisplatin
;
Diagnosis
;
Disease Progression
;
Drug Therapy
;
Epirubicin
;
Fluorouracil
;
Follow-Up Studies
;
Humans
;
Korea
;
Medical Records
;
Mortality
;
Nasopharyngeal Neoplasms
;
Neck
;
Osteosarcoma
;
Pediatrics
;
Radiotherapy
;
Retrospective Studies
;
Seoul
;
Shock, Septic
;
Survival Rate
9.Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors.
Tchan Kyu PARK ; Soo Nyung KIM ; Sang Wun KIM ; Gwi Eon KIM ; Chang Ok SUH
Journal of Korean Medical Science 2000;15(4):436-441
The aim of this study was to evaluate the survival of 395 previously untreated cervical cancer patients with at least one high risk factor following concurrent chemoradiation and to assess the toxicities. Two different chemotherapy regimens were used for concurrent chemoradiation. In the patients with squamous cell carcinoma, 100 mg/m2 of cisplatin was infused intravenously, followed immediately by five consecutive daily administrations of 5-fluorouracil, 1,000 mg/m2/day, each infused intravenously over 24 hr. As for the patients with adenocarcinoma, 70 mg/m2 of cisplatin, 250 mg/m2 of cytoxan and 45 mg/m2 of adriamycin were administered intravenously on days 1, 2, and 3, respectively. The 5-year survival rate was 54.4+ACU- with stage III and IV, 62.6+ACU- with lymph node metastasis on computed tomogram or MRI, 77.9+ACU- with stage I-II disease with lesion size +AD4- or +AD0-4 cm, and 50.3+ACU- with small cell carcinoma or adenocarcinoma. Side effects from concurrent chemoradiation such as nausea, vomiting, and alopecia were present in all 395 cases. Anemia, leukopenia, thrombocytopenia, hepatotoxicity, and nephrotoxicity were observed to varying degrees, but there was no toxic death. This study suggests that cisplatin-based concurrent chemoradiation in treating cervical cancer patients with high risk factors is effective and relatively well tolerated, with acceptable toxicity.
Adenocarcinoma/radiotherapy
;
Adenocarcinoma/mortality
;
Adenocarcinoma/drug therapy
;
Adult
;
Aged
;
Antineoplastic Agents, Combined/therapeutic use+ACo-
;
Antineoplastic Agents, Combined/adverse effects
;
Carboplatin/administration +ACY- dosage
;
Carcinoma, Squamous Cell/radiotherapy
;
Carcinoma, Squamous Cell/mortality
;
Carcinoma, Squamous Cell/drug therapy
;
Cervix Neoplasms/radiotherapy+ACo-
;
Cervix Neoplasms/mortality
;
Cervix Neoplasms/drug therapy
;
Chemotherapy, Adjuvant/adverse effects
;
Cisplatin/administration +ACY- dosage
;
Combined Modality Therapy
;
Comparative Study
;
Cyclophosphamide/administration +ACY- dosage
;
Doxorubicin/administration +ACY- dosage
;
Female
;
Fluorouracil/administration +ACY- dosage
;
Gastrointestinal Diseases/etiology
;
Gastrointestinal Diseases/epidemiology
;
Hematologic Diseases/etiology
;
Hematologic Diseases/epidemiology
;
Hepatitis, Toxic/etiology
;
Hepatitis, Toxic/epidemiology
;
Human
;
Kidney Diseases/epidemiology
;
Kidney Diseases/chemically induced
;
Korea/epidemiology
;
Life Tables
;
Lymphatic Metastasis
;
Middle Age
;
Particle Accelerators
;
Radiotherapy, High-Energy+ACo-/adverse effects
;
Retrospective Studies
;
Risk
;
Survival Analysis
;
Treatment Outcome
10.Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors.
Tchan Kyu PARK ; Soo Nyung KIM ; Sang Wun KIM ; Gwi Eon KIM ; Chang Ok SUH
Journal of Korean Medical Science 2000;15(4):436-441
The aim of this study was to evaluate the survival of 395 previously untreated cervical cancer patients with at least one high risk factor following concurrent chemoradiation and to assess the toxicities. Two different chemotherapy regimens were used for concurrent chemoradiation. In the patients with squamous cell carcinoma, 100 mg/m2 of cisplatin was infused intravenously, followed immediately by five consecutive daily administrations of 5-fluorouracil, 1,000 mg/m2/day, each infused intravenously over 24 hr. As for the patients with adenocarcinoma, 70 mg/m2 of cisplatin, 250 mg/m2 of cytoxan and 45 mg/m2 of adriamycin were administered intravenously on days 1, 2, and 3, respectively. The 5-year survival rate was 54.4+ACU- with stage III and IV, 62.6+ACU- with lymph node metastasis on computed tomogram or MRI, 77.9+ACU- with stage I-II disease with lesion size +AD4- or +AD0-4 cm, and 50.3+ACU- with small cell carcinoma or adenocarcinoma. Side effects from concurrent chemoradiation such as nausea, vomiting, and alopecia were present in all 395 cases. Anemia, leukopenia, thrombocytopenia, hepatotoxicity, and nephrotoxicity were observed to varying degrees, but there was no toxic death. This study suggests that cisplatin-based concurrent chemoradiation in treating cervical cancer patients with high risk factors is effective and relatively well tolerated, with acceptable toxicity.
Adenocarcinoma/radiotherapy
;
Adenocarcinoma/mortality
;
Adenocarcinoma/drug therapy
;
Adult
;
Aged
;
Antineoplastic Agents, Combined/therapeutic use+ACo-
;
Antineoplastic Agents, Combined/adverse effects
;
Carboplatin/administration +ACY- dosage
;
Carcinoma, Squamous Cell/radiotherapy
;
Carcinoma, Squamous Cell/mortality
;
Carcinoma, Squamous Cell/drug therapy
;
Cervix Neoplasms/radiotherapy+ACo-
;
Cervix Neoplasms/mortality
;
Cervix Neoplasms/drug therapy
;
Chemotherapy, Adjuvant/adverse effects
;
Cisplatin/administration +ACY- dosage
;
Combined Modality Therapy
;
Comparative Study
;
Cyclophosphamide/administration +ACY- dosage
;
Doxorubicin/administration +ACY- dosage
;
Female
;
Fluorouracil/administration +ACY- dosage
;
Gastrointestinal Diseases/etiology
;
Gastrointestinal Diseases/epidemiology
;
Hematologic Diseases/etiology
;
Hematologic Diseases/epidemiology
;
Hepatitis, Toxic/etiology
;
Hepatitis, Toxic/epidemiology
;
Human
;
Kidney Diseases/epidemiology
;
Kidney Diseases/chemically induced
;
Korea/epidemiology
;
Life Tables
;
Lymphatic Metastasis
;
Middle Age
;
Particle Accelerators
;
Radiotherapy, High-Energy+ACo-/adverse effects
;
Retrospective Studies
;
Risk
;
Survival Analysis
;
Treatment Outcome